The Role of microRNAs in the Biology of Rare Diseases

Rare diseases (RD) are characterized by low prevalence and affect not more than five individuals per 10,000 in the European population; they are a large and heterogeneous group of disorders including more than 7,000 conditions and often involve all organs and tissues, with several clinical subtypes within the same disease. Very often information concerning either diagnosis and/or prognosis on many RD is insufficient. microRNAs are a class of small non-coding RNAs that regulate gene expression at the posttranscriptional level by either degrading or blocking translation of messenger RNA targets. Recently, microRNA expression patterns of body fluids underscored their potential as noninvasive biomarkers for various diseases. The role of microRNAs as potential biomarkers has become particularly attractive. The identification of disease-related microRNAs is essential for understanding the pathogenesis of diseases at the molecular level, and is critical for designing specific molecular tools for diagnosis, treatment and prevention. Computational analysis of microRNA-disease associations is an important complementary means for prioritizing microRNAs for further experimental examination. In this article, we explored the added value of miRs as biomarkers in a selected panel of RD hitting different tissues/systems at different life stages, but sharing the need of better biomarkers for diagnostic and prognostic purposes.

[1]  Domenica Taruscio,et al.  Altered microRNA Expression Patterns in Hepatoblastoma Patients. , 2009, Translational oncology.

[2]  K. Jażdżewski,et al.  MicroRNAs in thyroid cancer. , 2011, The Journal of clinical endocrinology and metabolism.

[3]  Ankit Malhotra,et al.  miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. , 2011, Cancer research.

[4]  H. Soifer,et al.  MicroRNAs in disease and potential therapeutic applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[6]  D. Taruscio,et al.  MicroRNA profiling of multiple osteochondromas: identification of disease‐specific and normal cartilage signatures , 2010, Clinical genetics.

[7]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[8]  P. Jin,et al.  Noncoding RNAs in mental retardation , 2009, Clinical genetics.

[9]  J. Mattick,et al.  Raising the estimate of functional human sequences. , 2007, Genome research.

[10]  John McAnally,et al.  MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice , 2009, Science.

[11]  P. Pagel,et al.  MicroRNA‐492 is processed from the keratin 19 gene and up‐regulated in metastatic hepatoblastoma , 2011, Hepatology.

[12]  Wei Zhang,et al.  Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes , 2009, RNA biology.

[13]  S. Landais,et al.  Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. , 2007, Cancer research.

[14]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[15]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[16]  Alison Abbott,et al.  Rare-disease project has global ambitions , 2011, Nature.

[17]  I. Screpanti,et al.  Complex multipathways alterations and oxidative stress are associated with Hailey–Hailey disease , 2010, The British journal of dermatology.

[18]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[19]  G. Meola,et al.  Common micro‐RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[21]  D. Cacchiarelli,et al.  miRNAs as serum biomarkers for Duchenne muscular dystrophy , 2011, EMBO molecular medicine.

[22]  G. Russo,et al.  MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome , 2011, Cell Death and Disease.

[23]  George Coukos,et al.  Mechanisms of microRNA deregulation in human cancer , 2008, Cell cycle.

[24]  I. Screpanti,et al.  Oxidative stress activation of miR‐125b is part of the molecular switch for Hailey–Hailey disease manifestation , 2011, Experimental dermatology.

[25]  D. Cacchiarelli,et al.  MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. , 2010, Cell metabolism.

[26]  N. Park,et al.  miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. , 2011, Biochemical and biophysical research communications.

[27]  S. Lyonnet,et al.  microRNAs in diseases: from candidate to modifier genes , 2010, Clinical genetics.

[28]  L. Kemény,et al.  MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. , 2011, The Journal of investigative dermatology.

[29]  Annick Harel-Bellan,et al.  The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation , 2006, Nature Cell Biology.

[30]  L. Kunkel,et al.  Correction for Eisenberg et al., Distinctive patterns of microRNA expression in primary muscular disorders , 2008, Proceedings of the National Academy of Sciences.

[31]  George A Calin,et al.  MicroRNAs and cancer--new paradigms in molecular oncology. , 2009, Current opinion in cell biology.

[32]  A. Nakamura,et al.  Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy , 2011, PloS one.

[33]  J. Chi,et al.  MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. , 2010, Blood.

[34]  A. Nakamura,et al.  MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. , 2008, Cell structure and function.

[35]  M. Esteller,et al.  Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome , 2010, Epigenetics.

[36]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[37]  L. van der Fits,et al.  MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. , 2011, The Journal of investigative dermatology.

[38]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[39]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[40]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.